Intracranial infections caused by multidrug-resistant Gram-negative bacteria is a difficult problem in clinical treatment. Tigecycline, a novel antibiotic, has demonstrated potential against multidrug-resistant Gram-negative bacteria and has become an important option for treating intracranial infections. This article reviewed the research progress of tigecycline in treating intracranial infections, including its antimicrobial mechanism, pharmacokinetic characteristics, and therapeutic efficacy. It also pointed out that the safety of tigecycline treatment needed further verification. It was recommended to minimize the potential risks of tigecycline in the treatment for intracranial infections, balance the efficacy and safety, and achieve optimal treatment through individualized treatment plans, combination therapy, pharmaceutical monitoring and evaluation in clinical practice.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |